INTRODUCTION
In this report, we utilized a lipophilic fluorescent marker, PKH, to understand the heterogeneity within MM populations and to determine the effects of niches on the heterogeneity of MM cells (1) . The intensity of PKH staining decreases with each cell division in a linear fashion, resulting in the labeling of quiescent cells within a proliferating population (2, 3) .
We allowed the PKH labeled MM cells to undergo the cell cycle within NOD/SCID mice, and we tracked the PKH+ cells in different niches. In particular, we focused on analyzing the effects of different niches within the bone on MM cells because the bone marrow localization of MM cells is reminiscent of hematopoietic stem cells (4) . Analysis of 70 NOD/SCID mice revealed that, after in vivo cycling, quiescent PKH+ cells prefer to reside in the endosteal/osteoblastic regions of the bone marrow as compared to the vascular regions or spleen. PKH+ cells from the osteoblastic niche (PKH+/OS) readily formed into colonies in PHA-LCM medium. The PKH+ MM cells were also highly proliferative in secondary xenograft assays and were resistant to select drugs, as compared to the PKH-MM cells. Our report is the first to show that quiescent MM cells have a preference for niches. Given that bone marrow provides a protective environment for MM cells to proliferate and survive during treatment, it is important to target these interactions to improve the efficacies of the current therapies and to eventually improve patient survival. Figure 1A) . Therefore, we performed all the following analyses at 48 h post-transplantation.
Mice were sacrificed 48 h post-transplantation with PKH67+ cells, and the number of PKH67+ cells in each niche was analyzed using FACS. After averaging a total of 70 mice, 11.56% of the PKH67+ RPMI MM cells were recovered from the osteoblastic niche, 7.65% from the vascular niche, and 4.3% from the spleen. For the NCI MM cells, 18.3% of the cells were recovered from the osteoblastic niche, 8.9%
were recovered from the vascular niche, and 3.4% were recovered from the spleen ( Figure 1A and Supplemental Table 1 To increase osteoblastic niche specificity, we removed the monocyte lineages from the patient cells using CD14 antibodies. Slightly increased osteoblastic engraftment rates were observed upon transplantation of PKH+CD138-cells compared to the PKH+CD138+ cells. The osteoblastic niche was still a favorable niche for both cell populations (Supplemental Table 2 ). We then compared the phenotypes of the CD138-MM cells with previously published MM stem-like cells using FACS analysis.
The CD138-MM cells were enriched with CD20 and CD27 cell surface markers, as previously reported (5) We then measured the clonogenic properties of these cells using the PHA-LCM methylcellulose assay (5) . As compared to the cells from other niches, the PKH+ cells isolated from the osteoblastic niche (PKH+/OS) formed the most colonies in PHA-LCM medium ( Figure 1D, Supplemental Table 3 ). Although some PKH67+ cells were found in the spleen (PKH+/SP), those cells failed to form colonies. The colonies derived from RPMI or NCI cells contained the same light chain restriction patterns as the parental cell lines (Supplemental Figure 3A) . These data suggest that PKH+/OS cells are readily equipped to form colonies in vitro, which suggests that the niches that the cells reside in in vivo can influence the cells' properties.
We then transplanted these cells in secondary recipient mice to observe the ability of the PKH+/OS cells to form tumors (Supplemental Figure 3B) . After 3 months, the organs were isolated from each mouse and were evaluated for tumor engraftment by FACS analyses using human CD138 as a marker. The PKH+ CD138+ cells showed a significantly higher level of engraftment in the secondary mice than the PKH-CD138+ cells (Figure 2A) . Interestingly, the PKH+ RPMI cells from the osteoblastic niches (20%) showed a higher CD138+ engraftment rate than the PKH+ cells from the vascular niche (~7%) or the spleen (~5%) (Figure 2B) . However, the PKH+/OS cells from the NCI cells engrafted to the OS, VS, and spleen at comparable levels, indicating that the homing ability of the NCI MM cells to locate to specific niches was somehow lost during serial transplantation. Immunohistochemistry results also supported the data from FACS analyses ( Figure 2C) . The increased clonogenic activity or tumorigenic properties of the PKH+ cells were not due to differences in cell viability. Only live cells were sorted based on 7-AAD staining, prior to transplantation to the secondary xenografts (Supplemental Figure 3C) , and both the PKH+ and PKH-cells showed similar viability in vitro (Supplemental Figure 3D ).
Because cellular quiescence or stem-like properties are often linked to drug resistance in some tumors (6), we tested the drug susceptibility of the PKH+ or PKH-CD138+ cells in vitro using bortezomib, cyclophosphamide (CTX), vincristine (VCR), rituximab and prednisone (PD). Regardless of where the cells were isolated from, the PKH+ cells were more resistant to the drugs than the PKH-cell populations ( Figures   2D) . In summary, our report is the first show that quiescent MM cells preferably reside within osteoblastic niches. We discovered that both osteoblastic and vascular niches in 
